



Gastrointestinal inflammation and associated immune activation in schizophrenia

Emily G. Severance^{a,*}, Armin Alaedini^b, Shuojia Yang^a, Meredith Halling^a, Kristin L. Gressitt^a, Cassie R. Stallings^c, Andrea E. Origoni^c, Crystal Vaughan^c, Sunil Khushalani^d, F. Markus Leweke^{d,e}, Faith B. Dickerson^c, Robert H. Yolken^a

^a Stanley Division of Developmental Neurovirology, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Blalock 1105, Baltimore, MD, 21287-4933, United States

^b Department of Medicine, Columbia University Medical Center, New York, NY, 10032, United States

^c Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, 21201, United States

^d Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Ruprecht-Karls-University Heidelberg, Mannheim, Germany

^e Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany

ARTICLE INFO

Article history:

Received 22 November 2011

Received in revised form 20 February 2012

Accepted 22 February 2012

Available online 24 March 2012

Keywords:

Immunology

Environment

Food hypersensitivity

Microbiology

Mental disorder

Intestine

ABSTRACT

Immune factors are implicated in normal brain development and in brain disorder pathogenesis. Pathogen infection and food antigen penetration across gastrointestinal barriers are means by which environmental factors might affect immune-related neurodevelopment. Here, we test if gastrointestinal inflammation is associated with schizophrenia and therefore, might contribute to bloodstream entry of potentially neurotropic milk and gluten exorphins and/or immune activation by food antigens. IgG antibodies to *Saccharomyces cerevisiae* (ASCA, a marker of intestinal inflammation), bovine milk casein, wheat-derived gluten, and 6 infectious agents were assayed. Cohort 1 included 193 with non-recent onset schizophrenia, 67 with recent onset schizophrenia and 207 non-psychiatric controls. Cohort 2 included 103 with first episode schizophrenia, 40 of whom were antipsychotic-naïve. ASCA markers were significantly elevated and correlated with food antigen antibodies in recent onset and non-recent onset schizophrenia compared to controls ($p \leq 0.00001$ – 0.004) and in unmedicated individuals with first episode schizophrenia compared to those receiving antipsychotics ($p \leq 0.05$ – 0.01). Elevated ASCA levels were especially evident in non-recent onset females ($p \leq 0.009$), recent onset males ($p \leq 0.01$) and in antipsychotic-naïve males ($p \leq 0.03$). Anti-food antigen antibodies were correlated to antibodies against *Toxoplasma gondii*, an intestinally-infectious pathogen, particularly in males with recent onset schizophrenia ($p \leq 0.002$). In conclusion, gastrointestinal inflammation is a relevant pathology in schizophrenia, appears to occur in the absence of but may be modified by antipsychotics, and may link food antigen sensitivity and microbial infection as sources of immune activation in mental illness.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

Immune factors are increasingly the focus of research that explores gene–environmental interactions underlying the pathophysiology of schizophrenia (Yolken and Torrey, 2008; Shi et al., 2009; Stefansson et al., 2009; Abazyan et al., 2010; Brown, 2011). Prenatal exposure to microbial pathogens triggers inflammatory processes that may affect fetal neurodevelopment (Yolken and Torrey, 2008; Brown, 2011). Food antigens also activate the immune response and provide another means by which environmental factors might impact immune-related neurodevelopment. Adult individuals with psychiatric disorders such as schizophrenia and bipolar disorder exhibit increased humoral immune responses to food and microbial antigens (Dohan et al., 1972; Reichelt and Landmark, 1995; Yolken and Torrey, 2008; Dickerson et

al., 2010; Severance et al., 2010a,b; Cascella et al., 2011; Dickerson et al., 2011).

Food-specific antibody responses result from the entry of food antigens into the general circulation, presumably because of gastrointestinal (GI) inflammation or otherwise compromised GI epithelial and/or endothelial barriers. Bovine milk caseins and wheat glutens are of particular interest in neuropsychiatric disorders, because peptides derived from both can act as ligands of opioid receptors peripherally and in the central nervous system (Dohan, 1979; Reichelt et al., 1981; Drysdale et al., 1982; Cade et al., 1990; Reichelt and Stensrud, 1998). GI epithelial barriers can also be penetrated during an infection of the gut by enteric viruses or other microorganisms that are acquired through oral ingestion.

To determine if individuals with schizophrenia might possess a GI barrier defect that enables the passage of potentially detrimental antigens into the systemic circulation, we measured antibodies to anti-*Saccharomyces cerevisiae*, a marker of intestinal inflammation that is used as a diagnostic aid in Crohn's disease (Oshitani et al., 2000;

* Corresponding author. Tel.: +1 410 614 3918; fax: +1 410 955 3723.
E-mail address: eseverance@jhmi.edu (E.G. Severance).

Mallant-Hent et al., 2006; Desplat-Jego et al., 2007; Ashorn et al., 2009; Kotze et al., 2010). We then compared these measures to markers of exposure to food antigens and infectious agents in serum and plasma from individuals with non-recent onset and recent onset schizophrenia, medicated and unmedicated first episode schizophrenia, and controls who had no history of psychiatric illness. In these experiments, we found that GI inflammation may provide a common mechanism by which multiple sources of immune activation in schizophrenia might be linked.

2. Experimental/materials and methods

2.1. Study participants

2.1.1. Cohort 1 — Sheppard Pratt Health System, Baltimore, MD, USA

One hundred and ninety-three individuals with non-recent onset schizophrenia, 67 individuals with a recent onset of schizophrenia and 207 individuals who had no history of psychiatric disorders were recruited for this study. The methods for identifying and characterizing individuals of diagnostic groups according to criteria defined by DSM-IV have been previously described (Dickerson et al., 2010; Severance et al., 2010a, 2011).

For individuals with non-recent onset schizophrenia, inclusion criteria were: DSM-IV diagnosis of schizophrenia, schizophreniform disorder or schizoaffective disorder; age between 18 and 65, inclusive; and currently receiving antipsychotic medications. For individuals with recent onset of schizophrenia, inclusion criteria were: DSM-IV diagnosis of schizophrenia, schizophreniform disorder or schizoaffective disorder; the onset of psychotic symptoms for the first time within the past 24 months, defined as the presence of a positive psychotic symptom of at least moderate severity that lasted through the day for several days or occurred several times a week; age between 18 and 45, inclusive; and voluntary admission to either the inpatient or day hospital program. Individuals without a history of psychiatric disorder were recruited from posted announcements and were screened to rule out current or past psychiatric disorders with the Structured Clinical Interview for DSM-IV Axis I Disorders (First et al., 1998). Control participants were between the ages of 20 and 60, inclusive. Individuals with a diagnosis of recent onset schizophrenia had an average duration of illness of 0.78 ± 0.08 years, and those with non-recent onset schizophrenia had an average duration of illness of 20.98 ± 0.83 years.

Exclusion criteria for all three groups included the following: any history of intravenous substance abuse; mental retardation; and clinically significant medical disorder that would affect cognitive performance. With respect to substance abuse, for the recent onset group, psychosis that occurred only in the context of substance abuse, intoxication or withdrawal was the exclusion criterion; for the non-recent onset schizophrenia and control groups, current substance abuse that occurred over the past one month was the exclusion criterion.

Basic demographic data of the three cohort 1 study populations are shown in Table 1. Diagnostic groups differed significantly in age, sex and race in t-tests and/or chi-square tests. These variables were included in the multivariate analyses described below.

Blood samples were obtained by venipuncture, and plasma and serum separated and assessed for antibodies in the assays described below.

The studies were approved by the Institutional Review Boards (IRB) of the Sheppard Pratt Health System and the Johns Hopkins Medical Institution following established guidelines. All participants provided written informed consent after study procedures were explained. The work described was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

2.1.2. Cohort 2 — University of Cologne, Cologne, Germany

The methods for identifying and characterizing the individuals with a first episode of schizophrenia according to criteria defined by DSM-IV have also been previously described (Leweke et al., 2004). Forty of these patients were antipsychotic-naïve and 63 patients were currently receiving antipsychotic medication. Demographic data regarding age and sex are also listed in Table 1. The region from which patients were recruited was generally homogenous regarding socioeconomic characteristics. Informed consent was obtained from all study participants and procedures for sample collection and analysis were approved by the ethics committee at the University of Cologne in accordance with the Declaration of Helsinki.

2.2. Laboratory procedures

Anti-*Saccharomyces cerevisiae* IgG antibodies (ASCA) were measured according to the manufacturer's protocol using a commercially available kit (Orgentec, Mainz, Germany). IgG antibodies to bovine milk casein and wheat gluten were measured by ELISAs using

Table 1
Demographic information.

	n	Age Mean years + SEM ^a	Female n (%)	Male n (%)	African American n (%)	Caucasian/other n (%)
<i>Cohort 1 — Sheppard Pratt, Baltimore, MD, USA</i>						
Controls (CO)	207	32.07 ± 0.80	151 (72.95)	56 (27.05)	66 (31.88)	141 (68.12)
Non-recent onset schizophrenia (SZ)	193	42.01 ± 0.85 ^b	79 (40.93)	114 ^d (59.07)	102 ^f (53.85)	91 (47.15)
Recent onset schizophrenia (ROSZ)	67	22.28 ± 0.65 ^c	16 (23.88)	51 ^e (76.12)	31 ^g (46.27)	36 (53.73)
<i>Cohort 2 — University of Cologne, Cologne, Germany</i>						
First episode schizophrenia — medicated	63	29.38 ± 1.21	11 (17.5)	52 (82.5)	n/a	n/a
First episode schizophrenia — unmedicated	40	29.73 ± 1.47	13 (32.5)	27 (67.5)	n/a	n/a

^a SEM refers to standard error of the mean.

^b CO vs SZ $t = -8.57$, $p \leq 0.00001$.

^c CO vs ROSZ $t = 6.76$, $p < 0.00001$.

^d CO vs SZ $\chi^2 = 41.89$, $p \leq 0.0001$.

^e CO vs ROSZ $\chi^2 = 51.2$, $p \leq 0.0001$.

^f CO vs SZ $\chi^2 = 18.02$, $p \leq 0.0001$.

^g CO vs ROSZ $\chi^2 = 4.58$, $p \leq 0.032$.

previously described methods (Severance et al., 2010a). Whole casein was purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.). Whole gluten was extracted from the wheat cultivar Cheyenne as previously described (Samaroo et al., 2010). In brief, for both the casein and gluten immunoassays, plate wells were incubated with 100 ng protein in 50 μ l carbonate buffer (0.05 M carbonate-bicarbonate, pH 9.6; Sigma-Aldrich, St. Louis, MO, U.S.A.) overnight at 4 °C, and plates were blocked for 1 h at 37 °C with 1% (wt/vol) human serum albumin (Sigma-Aldrich, St. Louis, MO, U.S.A.) in PBS. Plates were then incubated with samples diluted 1:200 in PBST for 2 h at 37 °C. Plates were washed and incubated with peroxidase-conjugated goat-anti-human IgG secondary antibodies for 30 min at 37 °C (Southern Biotech, Birmingham, AL, U.S.A.). A 2,2'-azino-di-(3-ethylbenzthiazoline-6-sulfonate) and 0.02% hydrogen peroxide solution (KPL Protein Research Products, Gaithersburg, MD, U.S.A.) was added for color development, and absorbance was measured at 405 nm, with a reference wavelength of 490 nm, in an automated microtiter plate reader (Molecular Devices, Menlo Park, CA, U.S.A.). Casein antibody measurements for a portion of the individuals tested in this study have been previously reported (Severance et al., 2010a).

Commercially available ELISA kits for measuring EBV IgG, Influenza A IgG, Influenza B IgG, Measles IgG, Rubella IgG, and *T. gondii* IgG were purchased from IBL America (Minneapolis, MN, U.S.A.) and/or IBL International GmbH (Hamburg, Germany). HSV-1 kits were purchased from Focus Diagnostics (Cypress, CA, U.S.A.). IgG levels to these infectious disease agents had been previously measured for a series of studies at the Stanley Division at Johns Hopkins.

2.3. Statistical analyses

For cohort 1, plate-to-plate variation was corrected by control mean-normalizing each plate so that the control individuals on any particular plate equaled a value of “1”, as previously described (Severance et al., 2010a). For cohort 2, because there were no control individuals, plates were mean-normalized so that the values for the medicated individuals were equal to “1”. In both cohorts, quantitative antibody levels to ASCA were compared using t-tests and two-tailed p-values. In cohort 1, multiple linear regressions corrected for age, sex and race were implemented to test for inter-correlations of ASCA, food antigen and infectious disease antigen IgG antibody levels. For cohort 2, multiple linear regressions corrected for age and sex were used to test for correlations among ASCA, casein and gluten in antipsychotic-positive versus antipsychotic-naïve individuals. Regression values that equaled or exceeded 0.15 and p values less than 0.05 were considered significant. For both cohorts, we broke down the diagnostic groups according to sex and race and applied the same analyses. We also examined correlations of ASCA with age. Statistical analyses were performed with STATA version 11 (STATA Corp LP, College Station, Texas, U.S.A.).

3. Results

In 467 blood samples obtained from Sheppard Pratt Health System in Baltimore, MD, U.S.A., the levels of ASCA antibodies were significantly elevated in both non-recent onset (1.45 ± 0.14 , $t = -2.86$, $p \leq 0.004$) and recent onset schizophrenia (2.03 ± 0.35 , $t = -4.2$, $p \leq 0.00001$) compared to controls (1.00 ± 0.08 ; Fig. 1, Panel A). When the diagnostic groups were broken down according to sex, females in the non-recent onset group had significantly elevated antibody levels compared to control females, but levels between males in these two groups were not significantly different (Fig. 1, Panel B). Conversely, in the recent onset group, males had statistically significant elevations in antibody levels compared to control males, whereas these differences were not detected between females in these two groups (Fig. 1, Panel B).

In the Sheppard Pratt cohort, levels of ASCA antibodies were significantly correlated with anti-casein and anti-gluten IgG in the non-recent onset group and with anti-gluten IgG in the recent onset group




Fig. 1. Quantitative ASCA IgG levels in individuals with schizophrenia compared to controls. CO refers to controls, Non-RO to non-recent onset, RO to recent onset and SZ to schizophrenia. P-values refer to the level of statistical significance following a two-tailed t-test. Panel A: Elevated ASCA IgG levels were found in individuals with Non-RO SZ and RO SZ compared to controls. Panel B: ASCA IgG levels were significantly elevated in females with Non-RO SZ compared to female controls and in males with RO SZ compared to male controls.

(Table 2). Following sex stratification, these correlations were significant in non-recent onset females compared to control females and in both sexes of the recent onset group compared to their respective control groups. Anti-casein and anti-gluten IgG levels were not significantly correlated with ASCA antibody levels in the non-psychiatric control group. Anti-casein and anti-gluten levels were significantly correlated to each other in all groups except for females with recent onset schizophrenia.

We then evaluated the effects of therapeutic treatment on these marker correlations using a cohort of 103 samples from Cologne, Germany, which was comprised of individuals with first episode schizophrenia, 40 of whom were antipsychotic-naïve. In this group, individuals who were antipsychotic-naïve had ASCA levels that were significantly higher (1.46 ± 0.20 , $t = -1.99$, $p \leq 0.05$) than those who received antipsychotic medications (1.0 ± 0.13 ; Fig. 2, Panel A). When these groups were broken down according to sex, only males who were antipsychotic-naïve showed significantly elevated ASCA levels (Fig. 2, Panel B). It was also only in the untreated group where anti-casein and anti-gluten IgG levels were significantly correlated with ASCA, and this finding was most apparent in women who were antipsychotic-naïve (Table 2). ASCA and antibodies to these food antigens were not significantly correlated in those receiving antipsychotic medication except for a modest correlation of ASCA with anti-casein IgG in men of this group (Table 2). As with the Baltimore cohort, anti-casein and anti-gluten IgG levels were very highly correlated (Table 2).

To determine if these correlations reflected a greater generalized immune activation, we reviewed previously collected cohort 1 data of antibodies directed at a variety of pathogenic microorganisms. With one exception, ASCA, anti-casein IgG and anti-gluten IgG levels were not strongly correlated with the infectious disease agent

Table 2
GI inflammation and food antigen antibody inter-correlations.

	n	Multiple linear regressions (corrected for age, sex, and race)		
		ASCA:casein	ASCA:gluten	Casein:gluten
		R ² , p-value	R ² , p-value	R ² , p-value
<i>Cohort 1 — Sheppard Pratt, Baltimore, MD, USA</i>				
Control	207	0.04, ns	0.07, ns	0.71, 0.00001
Female	151	0.025, ns	0.08, ns	0.70, 0.00001
Male	56	0.11, ns	0.11, ns	0.82, 0.00001
Non-recent onset schizophrenia	193	0.15, 0.00001	0.16, 0.00001	0.73, 0.00001
Female	79	0.18, 0.00001	0.23, .0002	0.80, 0.00001
Male	114	0.12, ns	0.10, ns	0.65, 0.00001
Recent onset schizophrenia	67	0.11, ns	0.41, 0.00001	0.46, 0.00001
Female	16	0.60, ns	0.84, 0.00001	0.41, ns
Male	51	0.10, ns	0.32, 0.001	0.45, 0.00001
<i>Cohort 2 — University of Cologne, Cologne, Germany</i>				
First episode schizophrenia — unmedicated	40	0.27, 0.01	0.21, 0.03	0.98, 0.00001
Female	13	0.45, 0.05	0.45, 0.05	0.99, 0.00001
Male	27	0.18, ns	0.14, ns	0.98, 0.00001
First episode schizophrenia — medicated	63	0.12, ns	0.10, ns	0.91, 0.00001
Female	11	0.07, ns	0.09, ns	0.98, 0.00001
Male	52	0.16, 0.01	0.11, ns	0.89, 0.00001

antibody levels in any diagnostic group (Fig. 3). In the recent onset group, we observed a significant correlation of casein IgG with *T. gondii* IgG ($R^2=0.23$, $p\leq0.002$), a finding that was specific to men in this group ($R^2=0.51$, $p\leq0.00001$). Men with recent onset schizophrenia also showed significant correlations of gluten IgG with *T. gondii* IgG ($R^2=0.24$, $p\leq0.0004$).

In neither cohort did we find significant effects of race or age on ASCA antibody levels or ASCA correlations with other antigens.




Fig. 2. ASCA IgG levels in individuals with schizophrenia according to medication status. SZ-unmed refers to antipsychotic-naïve schizophrenia, and SZ-med refers to antipsychotic-positive schizophrenia. P-values refer to the level of statistical significance following a two-tailed t-test. Panel A: ASCA IgG levels were elevated in individuals who were antipsychotic-naïve compared to those who received these medications. Panel B: ASCA IgG levels were significantly elevated in males who were antipsychotic-naïve compared to males who were antipsychotic-positive.

4. Discussion

The goal of our investigation was to evaluate if intestinal inflammation might be connected to food antigen-associated immune activation in individuals with schizophrenia and secondarily, to determine if this link was affected by antipsychotic medication. GI inflammation was elevated and was correlated with food antigen antibodies only in the schizophrenia groups, suggesting that disease-associated inflammation is one means by which caseins and glutes may gain entry into the systemic circulation and/or generate a humoral immune response. The ASCA markers were elevated in antipsychotic-naïve individuals suggesting a prevalence of this type of inflammation early in the course of disease, even before treatments are implemented. We also found a possible association between *T. gondii*-generated intestinal inflammation and anti-food antigen antibodies in the recent onset patient group. Infection of the GI tract, therefore, may be one factor modulating the development of antibodies to milk caseins and wheat glutes.

Over the years, strong associations between GI pathologies and psychiatric disorders have been reported, yet it has been difficult to distinguish cause from effect and characterize how antipsychotics impact GI symptoms (Reiter, 1926; Buscaino, 1953; Haug et al., 2002; Eaton et al., 2004; Hemmings, 2004; Alander et al., 2005; Pynnönen et al., 2005; Kalaydjian et al., 2006; Cascella et al., 2011). Particularly pertinent to our findings are autopsy examinations reporting extensive inflammatory changes throughout the GI tract of patients with psychiatric disorders and studies that examine associations of celiac disease with schizophrenia (Reiter, 1926; Buscaino, 1953; Dohan, 1970; Eaton et al., 2004; Hemmings, 2004; Pynnönen et al., 2005; Kalaydjian et al., 2006; Cascella et al., 2011). Autopsy results from one study of 82 patients with schizophrenia indicated that 50% had gastritis, 88% enteritis and 92% colitis (Buscaino, 1953; Hemmings, 2004). Celiac disease, an established risk factor for the development of schizophrenia, is characterized by inflammatory damage to intestinal villi following immune reaction to ingested wheat gluten (Eaton et al., 2004; Pynnönen et al., 2005; Kalaydjian et al., 2006; Cascella et al., 2011). These studies collectively support that structural damage to the GI tract is present in schizophrenia, and our results document via a new measure of inflammation that GI pathologies are evident and may occur independently of antipsychotic medication.

First and second generation antipsychotics are typically associated with GI motility issues such as constipation and bowel obstruction, but are also likely to affect cytokine balance and other aspects of immune function (Dome et al., 2007; Dean, 2010; Watanabe et al., 2010;




Fig. 3. Correlations of GI inflammation, food antigen IgG and IgG to infectious disease agents in the diagnostic groups. Anti-casein IgG, anti-gluten IgG and ASCA antibody levels were compared to each other as well as to IgG of the infectious disease antigens. Anti-casein IgG used as the Y-axis component is shown as a representative chart and refers to antibody levels following mean-normalized absorbance. P-values refer to the level of statistical significance following a multiple linear regression that was corrected for age, sex and race. For RO SZ, the p-value reported for ASCA reflects its significant correlation to gluten.

McNamara et al., 2011). In the Baltimore psychiatric groups, most of these individuals received antipsychotic medications at some point during their disease history and also at the time of the assessment, so it was not possible to evaluate whether medication status contributed to the GI-related correlations. Therefore, we included a study arm here specifically to address the medication issue through comparisons of individuals who were antipsychotic-naïve with those who received antipsychotics. We found no significant differences in anti-casein and anti-gluten IgG inter-associations between those who were medicated and those who were medication-free; however, for the ASCA inflammation marker, it was predominately the untreated group that retained significantly elevated levels of the marker as well as a correlation with the anti-food antigen IgGs. This finding suggests that antipsychotic agents may affect the type or degree of GI inflammation identified with ASCA, but that the disease-associated inflammation is present before the start of pharmacological treatment.

We also evaluated antibody level correlations of the food antigens with those of the infectious disease antigens to determine if the documented immune activation could be the result of multiple types of antigens creating a non-specific, activated immune state. We found that the food-based antigens, while significantly and expectedly inter-correlated, were generally not significantly correlated with antibodies to the infectious agents, with one important exception: antibodies to *T. gondii* were significantly associated with anti-casein antibodies in the recent onset group of the Baltimore cohort. The protozoan, *T. gondii*, a neurotropic parasite, is of particular interest here, in light of its association with the development of schizophrenia and its use as a model of inflammatory bowel disease in experimental animals (Liesenfeld, 2002; Mortensen et al., 2007; Torrey et al., 2007; Schreiner and Liesenfeld, 2009; Xiao et al., 2009; Yolken et al., 2009; Bereswill et al., 2010). Findings from our study suggest that infection with this protozoan may create altered GI permeability, which in turn may result in increased absorption of partially digested casein or gluten peptides. *T. gondii* relevance to schizophrenia may therefore include its role as an agent of intestinal inflammation in addition to its role as a neurotropic pathogen.

Many of the patterns uncovered in this study were sex-specific; however, full interpretations of these associations are limited by the low number of women in the recent onset schizophrenia group ($n = 16$) and in both groups of cohort 2 ($n = 11$ medicated, $n = 13$ antipsychotic-naïve). Nevertheless, elevated ASCA antibody levels and correlations of GI inflammation with the casein and gluten antibodies were found specifically in women with non-recent onset schizophrenia, a group where we had sufficient numbers of both sexes (males, $n = 114$; females, $n = 79$). This finding reinforces that the pathophysiology of this disease and its treatment likely impact men and women differently. For example, one interpretation of these data is that GI inflammation in men is particularly prevalent early on and resolves

over time, whereas women may have inflammation that persists throughout the course of the disease.

Overall, our results indicate that alterations in GI inflammation and permeability may contribute to the etiopathogenesis and/or symptomatology of schizophrenia. Genes may dictate those individuals who are especially susceptible to environmentally-induced barrier permeability issues. Some recently identified candidate genes that have particular relevance to mechanisms involving GI permeability and immune activation include vasoactive intestinal peptide receptor 2 (VIPR2), the major histocompatibility complex 2 (MHC2) and complement control-related genes (CSMD1 and CSMD2) (Shi et al., 2009; Stefansson et al., 2009; Havik et al., 2011; Vacic et al., 2011). Ultimately, an understanding of the interactions between intestinal inflammation and predisposing genetic factors may lead to new methods of identifying, treating and preventing psychotic disorders.

Role of funding source

This work was supported by the Stanley Medical Research Institute and by the Brain and Behavior Research Foundation (formerly NARSAD) where Dr. Severance is a Scott-Gentle Foundation Investigator. These funding sources had no role in study design, data collection and analyses, report writing and in the decision to submit the paper for publication.

Contributors

Drs. Severance and Yolken designed the study with input from Drs. Dickerson, Alaedini, and Leweke. All authors collected and/or analyzed data. Dr. Severance wrote the first draft of the manuscript. All authors approved the final manuscript.

Conflict of interest

The authors declare no conflicts of interest.

Acknowledgments

We thank Dr. Donald D. Kasarda of the U.S. Department of Agriculture for providing us with the wheat flour used for gluten extraction.

References

- Abazyan, B., Nomura, J., Kannan, G., Ishizuka, K., Tamashiro, K.L., Nucifora, F., Pogorelov, V., Ladenheim, B., Yang, C., Krasnova, I.N., Cadet, J.L., Pardo, C., Mori, S., Kamiya, A., Vogel, M.W., Sawa, A., Ross, C.A., Pletnikov, M.V., 2010. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. *Biol. Psychiatry* 68 (12), 1172–1181.
- Alander, T., Svardsudd, K., Johansson, S.E., Agreus, L., 2005. Psychological illness is commonly associated with functional gastrointestinal disorders and is important to consider during patient consultation: a population-based study. *BMC Med.* 3, 8.
- Ashorn, S., Valineva, T., Kaukinen, K., Ashorn, M., Braun, J., Raukola, H., Rantala, I., Collin, P., Maki, M., Luukkaala, T., Ilanen, S., 2009. Serological responses to microbial antigens in celiac disease patients during a gluten-free diet. *J. Clin. Immunol.* 29 (2), 190–195.
- Bereswill, S., Munoz, M., Fischer, A., Plickert, R., Haag, L.M., Otto, B., Kuhl, A.A., Lodenkemper, C., Gobel, U.B., Heimesaat, M.M., 2010. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. *PLoS One* 5 (12), e15099.
- Brown, A.S., 2011. The environment and susceptibility to schizophrenia. *Prog. Neurobiol.* 93 (1), 23–58.

- Buscaino, V., 1953. Patologia extraneurale della schizofrenia. Fegato, tubo digerente, sistema reticolo-endoteliale. *Acta Neurol.* VIII, 1–60.
- Cade, R., Wagemaker, H., Privette, R.M., Fregly, M.J., Rogers, J., Orlando, J., 1990. The effect of dialysis and diet on schizophrenia. *Psychiatry: World Perspect.* 3 (900), 494–500.
- Casella, N.G., Kryszak, D., Bhatti, B., Gregory, P., Kelly, D.L., Mc Evoy, J.P., Fasano, A., Eaton, W.W., 2011. Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. *Schizophr. Bull.* 37 (1), 94–100.
- Dean, B., 2010. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. *Int. J. Neuropsychopharmacol.* 14 (7), 997–1012.
- Desplat-Jego, S., Johanet, C., Escande, A., Goetz, J., Fabien, N., Olsson, N., Ballot, E., Sarles, J., Baudon, J.J., Grimaud, J.C., Veyrac, M., Chamouard, P., Humbel, R.L., 2007. Update on anti-*Saccharomyces cerevisiae* antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. *World J. Gastroenterol.* 13 (16), 2312–2318.
- Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Leister, F., Yang, S., Krivogorsky, B., Alaedini, A., Yolken, R., 2010. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. *Biol. Psychiatry* 68 (1), 100–104.
- Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Alaedini, A., Yolken, R., 2011. Markers of gluten sensitivity and celiac disease in bipolar disorder. *Bipolar Disord.* 13 (1), 52–58.
- Dohan, F.C., 1970. Celiac disease and schizophrenia. *Lancet* 1 (7652), 897–898.
- Dohan, F.C., 1979. Schizophrenia and neuroactive peptides from food. *Lancet* 1 (8124), 1031.
- Dohan, F.C., Martin, L., Grasberger, J.C., Boehme, D., Cottrell, J.C., 1972. Antibodies to wheat gliadin in blood of psychiatric patients: possible role of emotional factors. *Biol. Psychiatry* 5 (2), 127–137.
- Dome, P., Teleki, Z., Kotanyi, R., 2007. Paralytic ileus associated with combined atypical antipsychotic therapy. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 31 (2), 557–560.
- Drysdale, A., Deacon, R., Lewis, P., Olley, J., Electricwala, A., Sherwood, R., 1982. A peptide-containing fraction of plasma from schizophrenic-patients which binds to opiate receptors and induces hyperreactivity in rats. *Neuroscience* 7 (6), 1567–1573.
- Eaton, W., Mortensen, P.B., Agerbo, E., Byrne, M., Mors, O., Ewald, H., 2004. Celiac disease and schizophrenia: population based case control study with linkage of Danish national registers. *BMJ* 328 (7437), 438–439.
- First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1998. Structured Clinical Interview for DSM-IV Axis I Disorders – Non-patient Edition (SCID I/NP). Biometrics Research. New York State Psychiatric Institute, New York.
- Haug, T.T., Mykletun, A., Dahl, A.A., 2002. Are anxiety and depression related to gastrointestinal symptoms in the general population? *Scand. J. Gastroenterol.* 37 (3), 294–298.
- Havik, B., Le Hellard, S., Rietschel, M., Lybaek, H., Djurovic, S., Mattheisen, M., Muhleisen, T.W., Degenhardt, F., Priebe, L., Maier, W., Breuer, R., Schulze, T.G., Agartz, I., Melle, I., Hansen, T., Bramham, C.R., Nothen, M.M., Stevens, B., Werge, T., Andreassen, O.A., Cichon, S., Steen, V.M., 2011. The complement control-related genes C5MD1 and C5MD2 associate to schizophrenia. *Biol. Psychiatry* 70 (1), 35–42.
- Hemmings, G., 2004. Schizophrenia. *Lancet* 364 (9442), 1312–1313.
- Kalaydjian, A.E., Eaton, W., Casella, N., Fasano, A., 2006. The gluten connection: the association between schizophrenia and celiac disease. *Acta Psychiatr. Scand.* 113 (2), 82–90.
- Kotze, L.M., Nishihara, R.M., Utiyama, S.R., Kotze, P.G., Theiss, P.M., Olandoski, M., 2010. Antibodies anti-*Saccharomyces cerevisiae* (ASCA) do not differentiate Crohn's disease from celiac disease. *Arg. Gastroenterol.* 47 (3), 242–245.
- Leweke, F.M., Gerth, C.W., Koethe, D., Klosterkotter, J., Ruslanova, I., Krivogorsky, B., Torrey, E.F., Yolken, R.H., 2004. Antibodies to infectious agents in individuals with recent onset schizophrenia. *Eur. Arch. Psychiatry Clin. Neurosci.* 254 (1), 4–8.
- Liesenfeld, O., 2002. Oral infection of C57BL/6 mice with *Toxoplasma gondii*: a new model of inflammatory bowel disease? *J. Infect. Dis.* 185 (Suppl 1), S96–S101.
- Mallant-Hent, R., Mary, B., von Blomberg, E., Yuksel, Z., Wahab, P.J., Gundy, C., Meyer, G.A., Mulder, C.J., 2006. Disappearance of anti-*Saccharomyces cerevisiae* antibodies in celiac disease during a gluten-free diet. *Eur. J. Gastroenterol. Hepatol.* 18 (1), 75–78.
- McNamara, R.K., Jandacek, R., Rider, T., Tso, P., 2011. Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats. *Eur. J. Pharmacol.* 652 (1–3), 152–156.
- Mortensen, P.B., Norgaard-Pedersen, B., Waltoft, B.L., Sorensen, T.L., Hougaard, D., Yolken, R.H., 2007. Early infections of *Toxoplasma gondii* and the later development of schizophrenia. *Schizophr. Bull.* 33 (3), 741–744.
- Oshitani, N., Hato, F., Matsumoto, T., Jinno, Y., Sawa, Y., Hara, J., Nakamura, S., Seki, S., Arakawa, T., Kitano, A., Kitagawa, S., Kuroki, T., 2000. Decreased anti-*Saccharomyces cerevisiae* antibody titer by mesalazine in patients with Crohn's disease. *J. Gastroenterol. Hepatol.* 15 (12), 1400–1403.
- Pynnönen, P.A., Isometsä, E.T., Verkasalo, M.A., Kahkonen, S.A., Sipilä, I., Savilahti, E., Aalberg, V.A., 2005. Gluten-free diet may alleviate depressive and behavioural symptoms in adolescents with celiac disease: a prospective follow-up case-series study. *BMC Psychiatry* 5, 14.
- Reichelt, K.L., Landmark, J., 1995. Specific IgA antibody increases in schizophrenia. *Biol. Psychiatry* 37 (6), 410–413.
- Reichelt, K.L., Stensrud, M., 1998. Increase in urinary peptides prior to the diagnosis of schizophrenia. *Schizophr. Res.* 34 (3), 211–213.
- Reichelt, K.L., Hole, K., Hamberger, A., Saelid, G., Edminson, P.D., Braestrup, C.B., Lingjaerde, O., Ledaal, P., Orbeck, H., 1981. Biologically active peptide-containing fractions in schizophrenia and childhood autism. *Adv. Biochem. Psychopharmacol.* 28, 627–643.
- Reiter, P., 1926. Extrapyramidal motor disturbances in dementia praecox. *Acta Psychiatr. Neurol. (Kjøbenhavn)* 1, 287–304.
- Samaroo, D., Dickerson, F., Kasarda, D.D., Green, P.H., Briani, C., Yolken, R.H., Alaedini, A., 2010. Novel immune response to gluten in individuals with schizophrenia. *Schizophr. Res.* 118 (1–3), 248–255.
- Schreiner, M., Liesenfeld, O., 2009. Small intestinal inflammation following oral infection with *Toxoplasma gondii* does not occur exclusively in C57BL/6 mice: review of 70 reports from the literature. *Mem. Inst. Oswaldo Cruz* 104 (2), 221–233.
- Severance, E.G., Dickerson, F.B., Halling, M., Krivogorsky, B., Haile, L., Yang, S., Stallings, C.R., Origoni, A.E., Bossis, I., Xiao, J., Dupont, D., Haasnoot, W., Yolken, R.H., 2010a. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. *Schizophr. Res.* 118 (1–3), 240–247.
- Severance, E.G., Dupont, D., Dickerson, F.B., Stallings, C.R., Origoni, A.E., Krivogorsky, B., Yang, S., Haasnoot, W., Yolken, R.H., 2010b. Immune activation by casein dietary antigens in bipolar disorder. *Bipolar Disord.* 12 (8), 834–842.
- Severance, E.G., Dickerson, F.B., Viscidi, R.P., Bossis, I., Stallings, C.R., Origoni, A.E., Sullens, A., Yolken, R.H., 2011. Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. *Schizophr. Bull.* 37 (1), 101–107.
- Shi, J., Levinson, D.F., Duan, J., Sanders, A.R., Zheng, Y., Pe'er, I., Dudbridge, F., Holmans, P.A., Whittemore, A.S., Mowry, B.J., Olincy, A., Amin, F., Cloninger, C.R., Silverman, J.M., Buccola, N.G., Byerley, W.F., Black, D.W., Crowe, R.R., Oksenberg, J.R., Mirel, D.B., Kendler, K.S., Freedman, R., Gejman, P.V., 2009. Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature* 460 (7256), 753–757.
- Stefansson, H., Ophoff, R.A., Steinberg, S., Andreassen, O.A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O.P., Mors, O., Mortensen, P.B., Sigurdsson, E., Gustafsson, O., Nyegaard, M., Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist, J., Paunio, T., Borglum, A.D., Hartmann, A., Fink-Jensen, A., Nordentoft, M., Hougaard, D., Norgaard-Pedersen, B., Bottcher, Y., Olesen, J., Breuer, R., Moller, H.J., Giegling, I., Rasmussen, H.B., Timm, S., Mattheisen, M., Bitter, I., Rethelyi, J.M., Magnusdottir, B.B., Sigmundsson, T., Olason, P., Masson, G., Gulcher, J.R., Haraldsson, M., Fossdal, R., Thorgeirsson, T.E., Thorsteinsdottir, U., Ruggeri, M., Tosato, S., Franke, B., Strengman, E., Kiemeny, L.A., Melle, I., Djurovic, S., Abramova, L., Kaleda, V., Sanjuan, J., de Frutos, R., Bramer, E., Vassos, E., Fraser, G., Ettinger, U., Picchioni, M., Walker, N., Touloupoulou, T., Need, A.C., Ge, D., Yoon, J.L., Shianna, K.V., Freimer, N.B., Cantor, R.M., Murray, R., Kong, A., Golimbet, V., Carracedo, A., Arango, C., Costas, J., Jonsson, E.G., Terenius, L., Agartz, I., Petursson, H., Nothen, M.M., Rietschel, M., Matthews, P.M., Muglia, P., Peltonen, L., St Clair, D., Goldstein, D.B., Stefansson, K., Collier, D.A., 2009. Common variants conferring risk of schizophrenia. *Nature* 460 (7256), 744–747.
- Torrey, E.F., Bartko, J.J., Lun, Z.R., Yolken, R.H., 2007. Antibodies to *Toxoplasma gondii* in patients with schizophrenia: a meta-analysis. *Schizophr. Bull.* 33 (3), 729–736.
- Vacic, V., McCarthy, S., Malhotra, D., Murray, F., Chou, H.H., Peoples, A., Makarov, V., Yoon, S., Bhandari, A., Corominas, R., Iakoucheva, L.M., Krastovshvsky, O., Krause, V., Larach-Walters, V., Welsh, D.K., Craig, D., Kelson, J.R., Gershon, E.S., Leal, S.M., Dell Aquila, M., Morris, D.W., Gill, M., Corvin, A., Insel, P.A., McClellan, J., King, M.C., Karayiorgou, M., Levy, D.L., DeLisi, L.E., Sebat, J., 2011. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. *Nature* 471 (7339), 499–503.
- Watanabe, Y., Someya, T., Nawa, H., 2010. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. *Psychiatry Clin. Neurosci.* 64 (3), 217–230.
- Xiao, J., Jones-Brando, L., Talbot Jr., C.C., Yolken, R.H., 2009. Differential effects of three canonical *Toxoplasma* strains on gene expression in human neuroepithelial cells. *Infect. Immun.* 79 (3), 1363–1373.
- Yolken, R.H., Torrey, E.F., 2008. Are some cases of psychosis caused by microbial agents? A review of the evidence. *Mol. Psychiatry* 13 (5), 470–479.
- Yolken, R.H., Dickerson, F.B., Torrey, E.F., 2009. *Toxoplasma* and schizophrenia. *Parasite Immunol.* 31 (11), 706–715.